Ephedrine bill
This article was originally published in The Tan Sheet
Executive Summary
NDMA testifies Dec. 15 against SB 564, a Wisconsin state bill that would classify ephedrine as a Schedule III controlled substance in that state. A national bill (HR 3216), NDMA noted, would remove the "exemption from the record-keeping and reporting requirements of the Chemical Diversion and Trafficking Act for drugs containing ephedrine as the only active medicinal ingredient." NDMA maintained to the Wisconsin Senate and Judiciary Committee that state legislation "should be deferred until the federal law can be signed by the President and implemented by the Drug Enforcement Administration." HR 3216 was signed into law by President Clinton on Dec. 17
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning